Effectiveness of whey peptide and ripening extract of hop for Japanese patients of mild Alzheimer's disease

Effectiveness of whey peptide and ripening extract of hop for Japanese patients of mild Alzheimer's disease-prospective double-blind study (Kirin Alzheimer's Disease Project; KIRINAD) - (Kirin Alzheimer's Disease Project; KIRINAD)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031649

Enrollment

Registered

2018-03-09

Start date

2018-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with mild Alzheimer&#39

Interventions

Ripening extract of hop tablets (70mg/day) , 3 month Whey peptide (dipeptide

Trp-Tyr) Tablets (1g/day), 3 month placebo (maltodextrin) tablets (1g/day), 3 month

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Meeting the clinical criteria for Alzheimer's disease according to NINCDS-ADRDA, and features of brain MRI examination and brain blood flow of Single photon emission computed tomography (SPECT)

Exclusion criteria

Exclusion criteria: Patients with milk allergy (whey)

Design outcomes

Primary

Measure	Time frame
Estimating for effectiveness of ripening extract of hop and whey peptide containing high concentration of dipeptide (Trp-Tyr) for Japanese patients with mild Alzheimer's disease. 0W (Before); general blood test (including peripheral inflammation markers and phenotype of ApoE), psychological assessments (ADAS-Jcog, MMSE, POMS2) 12W; general blood test (including peripheral inflammation markers and phenotype of ApoE), psychological assessments (ADAS-Jcog, MMSE, POMS2) and SPECT 24W; general blood test (including peripheral inflammation markers and phenotype of ApoE), psychological assessments (ADAS-Jcog, MMSE, POMS2) 36W; general blood test (including peripheral inflammation markers and phenotype of ApoE), psychological assessments (ADAS-Jcog, MMSE, POMS2)	—

Measure

Time frame

Estimating for effectiveness of ripening extract of hop and whey peptide containing high concentration of dipeptide (Trp-Tyr) for Japanese patients with mild Alzheimer's disease. 0W (Before); general blood test (including peripheral inflammation markers and phenotype of ApoE), psychological assessments (ADAS-Jcog, MMSE, POMS2) 12W; general blood test (including peripheral inflammation markers and phenotype of ApoE), psychological assessments (ADAS-Jcog, MMSE, POMS2) and SPECT 24W; general blood test (including peripheral inflammation markers and phenotype of ApoE), psychological assessments (ADAS-Jcog, MMSE, POMS2) 36W; general blood test (including peripheral inflammation markers and phenotype of ApoE), psychological assessments (ADAS-Jcog, MMSE, POMS2)

—

Secondary

Measure	Time frame
Measurement of the frequencies for tolerance of ripening extract of hop (bitter taste) and whey peptide containing high concentration of dipeptide (Trp-Tyr) (abdominal bloating) for Japanese at 12W, 24W and 36W.	—

Countries

Japan

Contacts

Public ContactTohru Ohnuma

Juntendo University Department of Psychiatry

otoru@juntendo.ac.jp03-5802-1071

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Effectiveness of whey peptide and ripening extract of hop for Japanese patients of mild Alzheimer&#39;s disease